Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
PHASE1CompletedINTERVENTIONAL
Enrollment
14
Participants
Timeline
Start Date
August 31, 2013
Primary Completion Date
September 30, 2013
Study Completion Date
October 31, 2013
Conditions
Healthy
Interventions
DRUG
IPI-145
25 mg BID Oral Capsule
DRUG
Midazolam
2 mg midazolam syrup
Trial Locations (1)
66219
PRA International, Lenexa
All Listed Sponsors
lead
SecuraBio
INDUSTRY
NCT01925911 - Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam | Biotech Hunter | Biotech Hunter